ATE215065T1 - Verwendung von gamma-hydroxybuttersäureamiden in der behandlung von drogenabhängigkeit und insbesondere von alcoholismus - Google Patents

Verwendung von gamma-hydroxybuttersäureamiden in der behandlung von drogenabhängigkeit und insbesondere von alcoholismus

Info

Publication number
ATE215065T1
ATE215065T1 AT97941921T AT97941921T ATE215065T1 AT E215065 T1 ATE215065 T1 AT E215065T1 AT 97941921 T AT97941921 T AT 97941921T AT 97941921 T AT97941921 T AT 97941921T AT E215065 T1 ATE215065 T1 AT E215065T1
Authority
AT
Austria
Prior art keywords
alkyl
amides
treatment
halo
hydroxybutteric
Prior art date
Application number
AT97941921T
Other languages
English (en)
Inventor
Roberto Cacciaglia
Antonella Loche
Vincenzo Perlini
Lorenza Guano
Original Assignee
Ct Lab Farm Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Lab Farm Srl filed Critical Ct Lab Farm Srl
Application granted granted Critical
Publication of ATE215065T1 publication Critical patent/ATE215065T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Addiction (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
AT97941921T 1996-08-09 1997-08-07 Verwendung von gamma-hydroxybuttersäureamiden in der behandlung von drogenabhängigkeit und insbesondere von alcoholismus ATE215065T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT96MI001732A IT1283782B1 (it) 1996-08-09 1996-08-09 Uso di ammidi dell'acido gamma-idrossibutirrico nel trattamento di tossicodipendenze,ed in particolare sell'alcolismo
PCT/EP1997/004309 WO1998006690A1 (en) 1996-08-09 1997-08-07 USE OF η-HYDROXYBUTYRIC ACID AMIDES IN THE TREATMENT OF DRUG ADDICTION AND IN PARTICULAR OF ALCOHOLISM

Publications (1)

Publication Number Publication Date
ATE215065T1 true ATE215065T1 (de) 2002-04-15

Family

ID=11374795

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97941921T ATE215065T1 (de) 1996-08-09 1997-08-07 Verwendung von gamma-hydroxybuttersäureamiden in der behandlung von drogenabhängigkeit und insbesondere von alcoholismus

Country Status (13)

Country Link
US (2) US6436998B1 (de)
EP (1) EP0932597B1 (de)
JP (1) JP4259615B2 (de)
AT (1) ATE215065T1 (de)
AU (1) AU4379097A (de)
CA (1) CA2263328C (de)
DE (1) DE69711411T2 (de)
DK (1) DK0932597T3 (de)
ES (1) ES2174287T3 (de)
HU (1) HU228595B1 (de)
IT (1) IT1283782B1 (de)
PT (1) PT932597E (de)
WO (1) WO1998006690A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6472431B2 (en) 1998-12-23 2002-10-29 Orphan Medical, Inc. Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
FR2827859B1 (fr) 2001-07-30 2005-09-23 Lipha Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete
AU2003295393A1 (en) * 2002-11-01 2004-06-07 Baylor Research Institute Ghb treatment methods
US7838556B2 (en) * 2006-02-21 2010-11-23 University Of Maryland, Baltimore Ethers of 3-hydroxyphenylacetic acid as selective gamma-hydroxybutyric acid receptor ligands
EP2062875A1 (de) * 2007-11-13 2009-05-27 LABORATORIO FARMACEUTICO C.T. S.r.l. Neue polymorphe Formen von N-[4-(Trifluormethyl)benzyl]-4-Methoxybutyramid
US8778398B2 (en) 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
US8771735B2 (en) * 2008-11-04 2014-07-08 Jazz Pharmaceuticals, Inc. Immediate release dosage forms of sodium oxybate
MX391660B (es) 2010-03-24 2025-03-21 Jazz Pharmaceuticals Inc Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas
US8591922B1 (en) 2012-12-14 2013-11-26 Jazz Pharmacuticals, Inc. Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
ITMI20132041A1 (it) * 2013-12-06 2015-06-07 Ct Lab Farm Srl Derivati dell'acido gamma-idrossibutirrico, loro preparazione e loro uso medico.
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
ITUB20152860A1 (it) * 2015-08-04 2017-02-04 Laboratorio Farm C T S R L Selezionata amide dell?acido ?-idrossibutirrico e suoi usi nel trattamento dell?abuso da alcool
ITUA20164040A1 (it) * 2016-06-01 2017-12-01 Laboratorio Farm C T S R L Procedimento per la preparazione di polimorfo a
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
WO2020106735A1 (en) 2018-11-19 2020-05-28 Jazz Pharmaceuticals Ireland Limited Alcohol-resistant drug formulations
JP7553453B2 (ja) 2019-03-01 2024-09-18 フラメル アイルランド リミテッド 食事摂取状態における改善された薬物動態を有するガンマ－ヒドロキシ酪酸塩組成物
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
WO2022076824A1 (en) 2020-10-08 2022-04-14 Jazz Pharmaceuticals Ireland Limited Sodium oxybate to treat idiopathic hypersomnia
WO2023126076A1 (en) 2022-01-03 2023-07-06 Laboratorio Farmaceutico C.T. S.R.L. Medical use of an amide of y-hydroxybutyric acid in the treatment of fragile x syndrome
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
CN121038779A (zh) 2023-02-03 2025-11-28 特瑞斯制药公司 每晚一次的低钠羟丁酸盐组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940258A (en) * 1971-11-26 1976-02-24 Gaf Corporation Method for controlling aquatic weeds with N-phenylalkyl-γ-hydroxybutyramide
JPS6016432B2 (ja) * 1977-07-26 1985-04-25 グレラン製薬株式会社 複素環式化合物類およびその製造法
ES2052619T3 (es) * 1987-02-23 1994-07-16 Ono Pharmaceutical Co Un procedimiento para la preparacion de los nuevos derivados de tiazolidina.
IT1217783B (it) 1988-06-03 1990-03-30 Farmaceutico Ct S R L Lab Impiego di salo dell,acido gamma idrossi butirrico per la preparazione di composizioni farmaceutiche adatta ad essereimpiegate nella terapia dell,alcolismo e composizioni relative
IT1248588B (it) 1991-06-28 1995-01-19 Gaetano Crepaldi Composizioni farmaceutiche per la terapia dell'astinenza, del " craving", della dipendenza da sostanze stupefacenti, da sostanze psicoattive, da nicotina e dei disturbi alimentari.
EP0763016B1 (de) * 1994-06-01 2000-01-26 Axys Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur behandlung von durch mast-zellen verursachten krankheiten
RU2128165C1 (ru) * 1995-09-18 1999-03-27 Санкио Компани Лимитед Производные амидов и композиция, обладающая асат-ингибирующей активностью
ATE293603T1 (de) * 1997-10-14 2005-05-15 Mitsubishi Pharma Corp Piperazin-verbindungen und ihre medizinische verwendung

Also Published As

Publication number Publication date
HU228595B1 (en) 2013-04-29
AU4379097A (en) 1998-03-06
US6436998B1 (en) 2002-08-20
JP4259615B2 (ja) 2009-04-30
US6770784B2 (en) 2004-08-03
EP0932597A1 (de) 1999-08-04
US20020165224A1 (en) 2002-11-07
EP0932597B1 (de) 2002-03-27
DK0932597T3 (da) 2002-06-24
DE69711411D1 (de) 2002-05-02
ITMI961732A1 (it) 1998-02-09
CA2263328A1 (en) 1998-02-19
HUP9902437A3 (en) 2001-07-30
ITMI961732A0 (de) 1996-08-09
IT1283782B1 (it) 1998-04-30
PT932597E (pt) 2002-09-30
ES2174287T3 (es) 2002-11-01
DE69711411T2 (de) 2002-11-07
WO1998006690A1 (en) 1998-02-19
JP2000516225A (ja) 2000-12-05
CA2263328C (en) 2006-07-25
HUP9902437A2 (hu) 1999-12-28

Similar Documents

Publication Publication Date Title
ATE215065T1 (de) Verwendung von gamma-hydroxybuttersäureamiden in der behandlung von drogenabhängigkeit und insbesondere von alcoholismus
ES2117400T3 (es) Inhibidores de metaloproteinasas.
DE69429438D1 (de) Tricyclische carbamat-derivate zur inhibierung der g-protein funktion und für die behandlung von proliferativen erkrankungen
ATE219071T1 (de) Tricyclische verbindungen mit bindungsaffinität für melatoninrezeptoren, deren herstellung und verwendung
ES2191208T3 (es) Oxiimino-pregnano-carbolactonas.
IL134635A0 (en) A process for the preparation of acylated cyclic 1,3-dicarbonyl compounds
DE69911935D1 (de) Granulatimide-derivate zur behandlung von krebs
GR1000156B (el) ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΝΕΩΝ ΠΑΡΑΓΩΓΩΝ ΤΡΙΚΥΚΛΙΚΩΝ ΑΜΙΝΩΝ ΤΗΣ ΤΕΤΡΑΥΔΡΟ-5,6,7,8ΝΑΦΘΟ[2,3b] ΔΙΥΔΡΟ-2,3 ΦΟΥΡΑΝΗΣ & ΤΗΣ ΤΕΤΡΑΥΔΡΟ-6,7,8,9 5Η-ΒΕΝΖΟΚΥΚΛΟΕΠΤΑ[2,3Β] ΔΙΥΔΡΟ-2,3 ΦΟΥΡΑΝΗΣ.
BG103271A (en) Derivatives of n-(benzothiazol-2-yl) piperidine-1-ethaneamines, method for their preparation and application as therapeutical means
ITMI920084A1 (it) Alchil derivati del trazodone
ES2190533T3 (es) Derivados de tropano utilizables en particular para la deteccion in vivo de transportadores de dopamina.
DK0660822T3 (da) Cykliske benzylamino-, benzylamido- og benzylimidoderivater som antipsykotiske midler
BG101671A (bg) Диклавуланатна сол с диаминоетер и метод за получаването й
NO870423D0 (no) 5-substituert octahydroindolizin-analgetika-forbindelser og 7-keto-mellomprodukt.
DK7286A (da) Octahydroindoliziner
AR034088A1 (es) Composicion que comprende derivados anticonvulsivantes utiles en el tratamiento de esquizofrenia y el uso de dicho derivado para la manufactura de un medicamento
ATE118763T1 (de) Phenolisches amin als antimelanoma- und depigmentierungsmittel.
ATE219368T1 (de) Verwendung von prostanderivaten und deren kombination mit antibiotika in der behandlung bakterieller infektionen
DE69533833D1 (de) Verfahren zur Herstellung von Indolopyrrolocarbazol-Derivaten
GB1431617A (en) Benzopyrano- and benzothiopyranoindazole n-oxides
GB1410319A (en) 6-aza-3h-1,4-benzodiazepines

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification